## Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee endorsed the inclusion of dexamethasone on the core list of the EMLc for severe allergic reactions. In consideration of the need for corticosteroids for allergic disorders in children, the EMLc Subcommittee noted that dexamethasone injection was licensed for use in allergic disorders in children in some countries and is also used for non-allergic disorders, such as cerebral oedema, croup, post-operative nausea and vomiting and in the treatment of bacterial meningitis. While recognizing the need for systemic steroids in severe allergic reactions, the Subcommittee noted that for conditions such as allergic rhinitis and conjunctivitis, topical steroids or topical antihistamines have been shown to be effective and safer.